Skip to main content
. 2021 Jan 6;16(1):e0243862. doi: 10.1371/journal.pone.0243862

Fig 2. Mild EAE induced by MOG peptide immunization.

Fig 2

(a) Mice immunized with MOG peptide to induce EAE were treated daily with intranasal ST266 (n = 8 mice), <50 kDa ST266 (n = 8) or PBS (vehicle) (n = 8) from days 15–42 post-immunization, and control, non-EAE mice (n = 6) were treated with PBS. Mice were scored daily based on clinical signs of ascending paralysis. Mild EAE disease developed in all immunized groups with no difference in EAE scores between treatment groups (one-way repeated measures ANOVA p>0.05). (b) To estimate visual function, OKR testing was performed. Measurements were taken at baseline and then weekly for 6 weeks. In this cohort of mice with mild EAE disease, no significant vision loss developed compared with control mice, and no difference was detected in mean scores between treatment groups over time (one-way repeated measures ANOVA p>0.05) or at the final measurement on day 42 (one way ANOVA p >0.05). Data shown as mean +SEM.